C

cAMPfield Therapeutics

Develops oral PDE4 inhibitors for IBD

Director / Senior Director - Clinical Operations

Clinical Research OperationsUpdated on Nov 13
Full-timeBoston, MA, USANo salary listed

About the Job

Requirements

  • A bachelor's degree in life sciences or a related field is required; an advanced degree is preferred.
  • At least 10 years of clinical operations experience in biotech or pharmaceutical environments, including at least 5 years leading global Phase II or Phase III studies.
  • Experience overseeing contract research organizations and complex vendor ecosystems.
  • Strong understanding of global regulatory requirements, ICH-GCP, and operational best practices.
  • Ability to lead cross-functional teams and drive decisions in ambiguous, fast-moving environments.
  • Experience in inflammatory bowel disease is preferred but not required.
  • Prior experience at a small-to-mid-size biotech company is strongly preferred.

Responsibilities

  • Lead operational strategy, timelines, enrollment planning, and risk mitigation for a global Phase II clinical study.
  • Drive country and site selection strategy using feasibility data, historical performance, and patient-population insights.
  • Partner with Clinical Development to ensure protocol design is operationally feasible and aligned with scientific objectives.
  • Serve as the primary operational leader for the Phase II study and deliver key milestones, including first patient in, enrollment targets, database locks, and the clinical study report.
  • Oversee contract research organization performance, proactively resolve issues, provide quality oversight, and ensure adherence to key performance indicators.
  • Lead global study team meetings, decision-making, action tracking, and cross-functional alignment.
  • Monitor enrollment trends, site performance, and operational risks, implementing corrective actions as needed.
  • Oversee study vendors, including contract research organizations, central laboratories, imaging, electronic clinical outcome assessment, interactive response technology, and safety vendors, including selection, contracting input, and ongoing oversight.
  • Ensure global site engagement strategies are implemented in partnership with Site Engagement, Patient Recruitment, and Medical Affairs teams.
  • Support inspection readiness and ensure the trial master file is complete and high quality.
  • Partner with Biometrics and Data Management on data review plans, query management, and interim analysis readiness.
  • Ensure adherence to ICH-GCP, regulatory requirements, and internal standard operating procedures across regions.
  • Lead risk management and quality oversight, including issue escalation, corrective and preventive action development, and audit support.
  • Collaborate with Clinical Development, Regulatory, Safety, Chemistry, Manufacturing and Controls, and Program Management to ensure integrated planning and execution.
  • Provide operational input into key program deliverables, including investigator's brochure updates, regulatory submissions, and safety reviews.
  • Communicate study status, risks, and decisions to senior leadership and governance bodies.
  • Develop and manage the study budget, including vendor costs, site payments, and contingency planning.
  • Forecast resource needs and ensure appropriate staffing across internal and external teams.

Desired Qualifications

  • An advanced degree.
  • Experience in inflammatory bowel disease.
  • Prior experience at a small-to-mid-size biotech company.

About the Company

cAMPfield Therapeutics

Develops oral PDE4 inhibitors for IBD

cAMPfield Therapeutics develops oral small-molecule therapies for inflammatory and immunological diseases. Its lead program, prifemilast, is an oral PDE4 inhibitor being developed for inflammatory bowel disease (IBD), including ulcerative colitis. The drug’s mechanism targets PDE4 to reduce inflammation, and prifemilast has shown efficacy in Phase 2 studies for ulcerative colitis. The company focuses on in-licensing assets with potential to transform patient care and aims to establish prifemilast as a preferred IBD treatment with a favorable safety profile. Global rights to prifemilast (also known as HPP737) were acquired from vTv Therapeutics and Newsoara Biopharma. cAMPfield recently launched with a $180 million Series A led by top-tier investors, signaling growth plans and potential partnerships. The company’s goal is to bring a best-in-class oral PDE4 inhibitor to patients and pursue collaborations that advance its clinical programs.

Company size
11-50
Company stage
Series A
Total funding
$180M
Headquarters
San Diego, CA
Founded
2026

Recently Posted Jobs

Explore more opportunities at cAMPfield Therapeutics

See more jobs